AN Australian-Fijian medicinal kava health and wellness company Fiji Kava Ltd recorded $319,272 revenue for the second quarter of its 2021 financial year (three month ended December 31, 2020).
Listed on the Australia Securities Exchange (ASX) Fiji Kava’s revenue for the second quarter was an increase of 94 per cent from the first quarter of the year.
The financial overview of the company showed that its expenditure in operating activities in the quarter ending December 31, 2020 was $1283k, an increase of 22 per cent from the previous quarter, which was driven mainly because of the increased costs in product manufacturing.
Fiji Kava CEO Nicholas Simms said quarter two was a positive period for the company with positive revenue and the announcements of material new agreements to grow the availability of their products globally.
In his report in the financial statement, Mr Simms said, “While the nature of our business, the timing of new agreements and other external factors can result in short-term revenue fluctuations in any given quarter, we anticipate growing momentum over the medium to long term.
“Importantly during the quarter, we implemented new measures to better manage the ongoing challenges to minimise disruptions to our business.
“Included among these measures has been an increase of inventory to boost our product availability to meet demand, as we move forward.”
Mr Simms said they would continue to place a strategic emphasis on e-commerce as they invested in and developed their offering with partners to access new consumers and opportunities across key marketplaces.
Apart from a strong growth in its revenue in the quarter, Fiji Kava is carrying out repair works to the minor damage sustained at its facility in Levuka, Ovalau during STC Yasa, while its processing facility on the island continues to operate.
According to its financial report, the company continues to work with suppliers and community growers to understand the level of impact they sustained and any future implications.


